Search

Your search keyword '"Hiramatsu, N."' showing total 15 results
Start Over Author "Hiramatsu, N." Journal journal of viral hepatitis
15 results on '"Hiramatsu, N."'

2. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin

Author

Harada, N., Hiramatsu, N., Oze, T., Morishita, N., Yamada, R., Hikita, H., Miyazaki, M., Yakushijin, T., Miyagi, T., Yoshida, Y., Tatsumi, T., Kanto, T., Kasahara, A., Oshita, M., Mita, E., Hagiwara, H., Inui, Y., Katayama, K., Tamura, S., Yoshihara, H., Imai, Y., Inoue, A., Hayashi, N., and Takehara, T.

Published
2014
Full Text
View/download PDF

3. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses

Author

Inoue, Y., Hiramatsu, N., Oze, T., Yakushijin, T., Mochizuki, K., Hagiwara, H., Oshita, M., Mita, E., Fukui, H., Inada, M., Tamura, S., Yoshihara, H., Hayashi, E., Inoue, A., Imai, Y., Kato, M., Miyagi, T., Hohsui, A., Ishida, H., Kiso, S., Kanto, T., Kasahara, A., Takehara, T., and Hayashi, N.

Published
2010
Full Text
View/download PDF

6. Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin

Author

Oze, T., Hiramatsu, N., Uakushijin, T., Kurokawa, M., Igura, T., Mochizuki, K., Imanaka, K., Yamada, A., Oshita, M., Hagiwara, H., Mita, E., Ito, T., Inui, Y., Hijioka, T., Tamura, S., Yoshihara, H., Hayashi, E., Inoue, A., Imai, Y., Kato, M., Yoshida, Y., Tatsumi, T., Ohkawa, K., Kiso, S., Kanto, T., Kasahara, A., Takehara, T., and Hayashi, N.

Published
2009
Full Text
View/download PDF

7. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

Author

Hiramatsu, N., Oze, T., Yakushijin, T., Inoue, Y., Igura, T., Mochizuki, K., Imanaka, K., Kaneko, A., Oshita, M., Hagiwara, H., Mita, E., Nagase, T., Ito, T., Inui, Y., Hijioka, T., Katayama, K., Tamura, S., Yoshihara, H., Imai, Y., Kato, M., Yoshida, Y., Tatsumi, T., Ohkawa, K., Kiso, S., Kanto, T., Kasahara, A., Takehara, T., and Hayashi, N.

Published
2009
Full Text
View/download PDF

11. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1

Author

Oze, T., primary, Hiramatsu, N., additional, Yakushijin, T., additional, Yamada, R., additional, Harada, N., additional, Morishita, N., additional, Oshita, M., additional, Mita, E., additional, Ito, T., additional, Inui, Y., additional, Inada, M., additional, Tamura, S., additional, Yoshihara, H., additional, Imai, Y., additional, Kato, M., additional, Miyagi, T., additional, Yoshida, Y., additional, Tatsumi, T., additional, Kasahara, A., additional, Hayashi, N., additional, and Takehara, T., additional

Published
2014
Full Text
View/download PDF

12. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin

Author

Harada, N., primary, Hiramatsu, N., additional, Oze, T., additional, Morishita, N., additional, Yamada, R., additional, Hikita, H., additional, Miyazaki, M., additional, Yakushijin, T., additional, Miyagi, T., additional, Yoshida, Y., additional, Tatsumi, T., additional, Kanto, T., additional, Kasahara, A., additional, Oshita, M., additional, Mita, E., additional, Hagiwara, H., additional, Inui, Y., additional, Katayama, K., additional, Tamura, S., additional, Yoshihara, H., additional, Imai, Y., additional, Inoue, A., additional, Hayashi, N., additional, and Takehara, T., additional

Published
2013
Full Text
View/download PDF

13. Impaired ability of interferon‐alpha‐primed dendritic cells to stimulate Th1‐type CD4 T‐cell response in chronic hepatitis C virus infection

Author

Miyatake, H., primary, Kanto, T., additional, Inoue, M., additional, Sakakibara, M., additional, Kaimori, A., additional, Yakushijin, T., additional, Itose, I., additional, Miyazaki, M., additional, Kuzushita, N., additional, Hiramatsu, N., additional, Takehara, T., additional, Kasahara, A., additional, and Hayashi, N., additional

Published
2006
Full Text
View/download PDF

15. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.

Author

Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, and Hayashi N

Subjects
Aged, Dose-Response Relationship, Drug, Female, Genotype, Hepacivirus genetics, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Male, Middle Aged, Polyethylene Glycols administration & dosage, RNA, Viral blood, Recombinant Proteins, Treatment Outcome, Antiviral Agents therapeutic use, Hepacivirus isolation & purification, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
Abstract

Chronic hepatitis C (CH-C) genotype 1 patients who achieved early virologic response have a high probability of sustained virologic response (SVR) following pegylated interferon (Peg-IFN) plus ribavirin therapy. This study was conducted to evaluate how reducing drug doses affects complete early virologic response (c-EVR) defined as hepatitis C virus (HCV) RNA negativity at week 12. Nine hundred eighty-four patients with CH-C genotype 1 were enrolled. Drug doses were evaluated independently on a body weight base from doses actually taken. From multivariate analysis, the mean dose of Peg-IFN alpha-2b during the first 12 weeks was the independent factor for c-EVR (P = 0.02), not ribavirin. The c-EVR rate was 55% in patients receiving > or = 1.2 microg/kg/week of Peg-IFN, and declined to 38% at 0.9-1.2 microg/kg/week, and 22% in patients given <0.9 microg/kg/week (P < 0.0001). Even with stratified analysis according to ribavirin dose, the dose-dependent effect of Peg-IFN on c-EVR was observed, and similar c-EVR rates were obtained if the dose categories of Peg-IFN were the same. Furthermore, the mean dose of Peg-IFN during the first 12 weeks affected HCV RNA negativity at week 24 (P < 0.0001) and SVR (P < 0.0001) in a dose-dependent manner. Our results suggest that Peg-IFN was dose-dependently correlated with c-EVR, independently of ribavirin dose. Thus, maintaining the Peg-IFN dose as high as possible during the first 12 weeks can yield HCV RNA negativity and higher c-EVR rates, leading to better SVR rates in patients with CH-C genotype 1.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results